Abstract
Background: Artemisinin combination therapies have been wildly used in the treatment of uncomplicated falciparum malaria in most endemic countries. This strategy has been implemented in Cote d’Ivoire since 2005 with Artesunate + Amodiaquine (AS + AQ) and Artemether + lumefantrine (AL). The goal of this study was to assess efficacy and safety of these two drugs in two sentinel’s sites, Man and Abidjan in Cote d’Ivoire. Methods: An open label, randomized, clinical trial was conducted in Man in the west and Abidjan in the south of Cote d’Ivoire. Patients older than 6 months with uncomplicated falciparum malaria after consent were randomized in AS+AQ and AL group and were followed up for 42 days. The first endpoint was Adequate Clinical and Parasitological Response adjusted by PCR at day 42. The second endpoints were fever and parasite clearance time, crude cure rate at day 42 and safety of the two ACTs. Results: A total of 241 patients were randomized in AS+AQ (120) and AL (121) group. The crude cure rate at day 42 in PP analysis was 95.8% and 87.9% in AS+AQ and AL respectively. After correction by PCR ACPR at day 42 was 99.2% in AS+AQ group and 97.4% in AL group. The two ACTs were well tolerated. Conclusion: AS+AQ and AL remains efficacious in the uncomplicated malaria treatment in the two areas but continue monitoring is needed particularly for AL.
Highlights
Malaria remains a major public health problem instead of many strategies developed by World Health Organization (WHO) and his partners to control and eliminate this disease
AS+AQ and Artemether + Lumefantrine (AL) remains efficacious in the uncomplicated malaria treatment in the two areas but continue monitoring is needed for AL
Artemether + Lumefantrine (AL) and Artesunate + Amodiaquine (AS-AQ) are the widely available drugs, which are recommended by most malaria endemic countries in the treatment of uncomplicated falciparum malaria [2]
Summary
Malaria remains a major public health problem instead of many strategies developed by WHO and his partners to control and eliminate this disease. In malaria endemic Sub-Saharan countries pregnant women and children under-fives years are a high risk of malaria and death. Artemisinin Combination Therapy (ACT) associated with others control and elimination strategies are contributed to reduced malaria morbidity and mortality. Emergence and extension of resistance to artemisinins derivatives in South East Asia could counteract these benefits [1]. Artemether + Lumefantrine (AL) and Artesunate + Amodiaquine (AS-AQ) are the widely available drugs, which are recommended by most malaria endemic countries in the treatment of uncomplicated falciparum malaria [2]. Monitoring of artemisinin-based combination therapy (ACT) becomes important in the light of emergence of artemisinin resistance in South-East Asia [3,4]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: International Journal of Clinical Research & Trials
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
